ANNEXON, INC. Operating Cash Flow
ANNEXON, INC. (ANNX) reported Operating Cash Flow of -$94.80 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-12
- ANNEXON, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$48.01M.
- ANNEXON, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$46.80M.
- ANNEXON, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$45.93M.
- ANNEXON, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$52.30M.
- ANNEXON, INC. net cash provided by (used in) operating activities for fiscal 2025 was -$186.36M.
- ANNEXON, INC. net cash provided by (used in) operating activities for fiscal 2024 was -$118.01M.
- ANNEXON, INC. net cash provided by (used in) operating activities for fiscal 2023 was -$121.14M.
- ANNEXON, INC. net cash provided by (used in) operating activities for fiscal 2022 was -$116.31M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 3 month as first filed | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$48.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$94.80M 10-Q · filed 2026-08-12 | -$140.73M derived: sum of 3 quarters · filed 2026-08-12 | -$193.03M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2026-03-31 | -$46.80M 10-Q · filed 2026-05-07 | -$92.72M derived: sum of 2 quarters · filed 2026-05-07 | -$145.03M derived: sum of 3 quarters · filed 2026-05-07 | -$183.10M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-12-31 | -$45.93M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$98.23M derived: sum of 2 quarters · filed 2026-03-30 | -$136.30M derived: sum of 3 quarters · filed 2026-08-12 | -$186.36M 10-K · filed 2026-03-30 | |
| 2025-09-30 | -$52.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$90.38M derived: sum of 2 quarters · filed 2026-08-12 | -$140.43M 10-Q · filed 2025-11-10 | -$176.44M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-06-30 | -$38.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$88.13M 10-Q · filed 2026-08-12 | -$124.14M derived: sum of 3 quarters · filed 2026-08-12 | -$156.16M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-03-31 | -$50.05M 10-Q · filed 2026-05-07 | -$86.07M derived: sum of 2 quarters · filed 2026-05-07 | -$118.08M derived: sum of 3 quarters · filed 2026-05-07 | -$139.79M derived: sum of 4 quarters · filed 2026-05-07 | |
| 2024-12-31 | -$36.02M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$68.03M derived: sum of 2 quarters · filed 2026-03-30 | -$89.74M derived: sum of 3 quarters · filed 2026-03-30 | -$118.01M 10-K · filed 2026-03-30 | |
| 2024-09-30 | -$32.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$53.72M derived: sum of 2 quarters · filed 2025-11-10 | -$81.99M 10-Q · filed 2025-11-10 | -$105.47M derived: sum of 4 quarters · filed 2025-11-10 | |
| 2024-06-30 | -$21.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$49.98M 10-Q · filed 2025-08-14 | -$73.45M derived: sum of 3 quarters · filed 2025-08-14 | -$101.74M derived: sum of 4 quarters · filed 2025-08-14 | |
| 2024-03-31 | -$28.27M 10-Q · filed 2025-05-12 | -$51.74M derived: sum of 2 quarters · filed 2025-05-12 | -$80.03M derived: sum of 3 quarters · filed 2025-05-12 | -$116.42M derived: sum of 4 quarters · filed 2025-05-12 | |
| 2023-12-31 | -$23.48M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | -$51.77M derived: sum of 2 quarters · filed 2025-03-03 | -$88.15M derived: sum of 3 quarters · filed 2025-03-03 | -$121.14M 10-K · filed 2025-03-03 | |
| 2023-09-30 | -$28.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$64.67M derived: sum of 2 quarters · filed 2024-11-14 | -$97.67M 10-Q · filed 2024-11-14 | -$124.80M derived: sum of 4 quarters · filed 2024-11-14 | |
| 2023-06-30 | -$36.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | -$69.37M 10-Q · filed 2024-08-12 | -$96.51M derived: sum of 3 quarters · filed 2024-08-12 | -$127.23M derived: sum of 4 quarters · filed 2024-08-12 | |
| 2023-03-31 | -$32.99M 10-Q · filed 2024-05-13 | -$60.13M derived: sum of 2 quarters · filed 2024-05-13 | -$90.85M derived: sum of 3 quarters · filed 2024-05-13 | -$119.01M derived: sum of 4 quarters · filed 2024-05-13 | |
| 2022-12-31 | -$27.14M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | -$57.86M derived: sum of 2 quarters · filed 2024-03-26 | -$86.02M derived: sum of 3 quarters · filed 2024-03-26 | -$116.31M 10-K · filed 2024-03-26 | |
| 2022-09-30 | -$30.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$58.88M derived: sum of 2 quarters · filed 2023-11-13 | -$89.17M 10-Q · filed 2023-11-13 | -$117.49M derived: sum of 4 quarters · filed 2023-11-13 | |
| 2022-06-30 | -$28.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | -$58.45M 10-Q · filed 2023-08-07 | -$86.77M derived: sum of 3 quarters · filed 2023-08-07 | -$116.49M derived: sum of 4 quarters · filed 2023-08-07 | |
| 2022-03-31 | -$30.29M 10-Q · filed 2023-05-08 | -$58.61M derived: sum of 2 quarters · filed 2023-05-08 | -$88.32M derived: sum of 3 quarters · filed 2023-05-08 | -$112.96M derived: sum of 4 quarters · filed 2023-05-08 | |
| 2021-12-31 | -$28.32M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | -$58.04M derived: sum of 2 quarters · filed 2023-03-06 | -$82.67M derived: sum of 3 quarters · filed 2023-03-06 | -$106.11M 10-K · filed 2023-03-06 | |
| 2021-09-30 | -$29.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$54.35M derived: sum of 2 quarters · filed 2022-11-03 | -$77.79M 10-Q · filed 2022-11-03 | -$97.05M derived: sum of 4 quarters · filed 2022-11-03 | |
| 2021-06-30 | -$24.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | -$48.07M 10-Q · filed 2022-08-08 | -$67.33M derived: sum of 3 quarters · filed 2022-08-08 | -$80.91M derived: sum of 4 quarters · filed 2022-08-08 | |
| 2021-03-31 | -$23.44M 10-Q · filed 2022-05-09 | -$23.42M 10-Q · filed 2021-05-17 | -$42.70M derived: sum of 2 quarters · filed 2022-05-09 | -$56.28M derived: sum of 3 quarters · filed 2022-05-09 | -$66.53M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | -$19.26M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | -$32.84M derived: sum of 2 quarters · filed 2022-03-01 | -$43.09M derived: sum of 3 quarters · filed 2022-03-01 | -$53.09M 10-K · filed 2022-03-01 | |
| 2020-09-30 | -$13.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | -$23.83M derived: sum of 2 quarters · filed 2021-11-09 | -$33.83M 10-Q · filed 2021-11-09 | -$42.62M derived: sum of 4 quarters · filed 2021-11-09 | |
| 2020-06-30 | -$10.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | -$20.25M 10-Q · filed 2021-08-16 | -$29.04M derived: sum of 3 quarters · filed 2021-08-16 | -$35.91M derived: sum of 4 quarters · filed 2021-08-16 | |
| 2020-03-31 | -$10.00M 10-Q · filed 2021-05-17 | -$18.79M derived: sum of 2 quarters · filed 2021-05-17 | -$25.66M derived: sum of 3 quarters · filed 2021-05-17 | ||
| 2019-12-31 | -$8.79M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | -$15.66M derived: sum of 2 quarters · filed 2021-03-25 | -$28.36M 10-K · filed 2021-03-25 | ||
| 2019-09-30 | -$6.87M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-16 | -$19.57M 10-Q · filed 2020-11-16 | |||
| 2019-06-30 | -$12.70M 10-Q · filed 2020-09-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |